BRPI0712001B8 - composto 8-[6-amino-3-piridil] xantinas substituídas e composição farmacêutica contendo o dito composto - Google Patents
composto 8-[6-amino-3-piridil] xantinas substituídas e composição farmacêutica contendo o dito compostoInfo
- Publication number
- BRPI0712001B8 BRPI0712001B8 BRPI0712001A BRPI0712001A BRPI0712001B8 BR PI0712001 B8 BRPI0712001 B8 BR PI0712001B8 BR PI0712001 A BRPI0712001 A BR PI0712001A BR PI0712001 A BRPI0712001 A BR PI0712001A BR PI0712001 B8 BRPI0712001 B8 BR PI0712001B8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pyridyl
- amino
- pharmaceutical composition
- composition containing
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Chemical class 0.000 title abstract 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 title 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- DIVYESOURJTWDY-UHFFFAOYSA-N 8-(6-aminopyridin-3-yl)-3,7-dihydropurine-2,6-dione Chemical class C1=NC(N)=CC=C1C(N1)=NC2=C1C(=O)NC(=O)N2 DIVYESOURJTWDY-UHFFFAOYSA-N 0.000 abstract 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80503006P | 2006-06-16 | 2006-06-16 | |
| US60/805,030 | 2006-06-16 | ||
| US80556406P | 2006-06-22 | 2006-06-22 | |
| US60/805,864 | 2006-06-22 | ||
| US11/811,823 US7884100B2 (en) | 2006-06-16 | 2007-06-12 | Substituted 8-[6-amino-3-pyridyl]xanthines |
| US11/811,3823 | 2007-06-12 | ||
| PCT/US2007/013849 WO2007149277A2 (en) | 2006-06-16 | 2007-06-13 | Substituted 8-[6-amino-3-pyridyl]xanthines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0712001A2 BRPI0712001A2 (pt) | 2012-01-10 |
| BRPI0712001B1 BRPI0712001B1 (pt) | 2020-04-07 |
| BRPI0712001B8 true BRPI0712001B8 (pt) | 2021-05-25 |
Family
ID=56290980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0712001A BRPI0712001B8 (pt) | 2006-06-16 | 2007-06-13 | composto 8-[6-amino-3-piridil] xantinas substituídas e composição farmacêutica contendo o dito composto |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7884100B2 (enExample) |
| EP (1) | EP2029143B1 (enExample) |
| JP (1) | JP5417558B2 (enExample) |
| KR (1) | KR101413404B1 (enExample) |
| CN (1) | CN103145712A (enExample) |
| AU (1) | AU2007261568B2 (enExample) |
| BR (1) | BRPI0712001B8 (enExample) |
| CA (1) | CA2655598C (enExample) |
| DK (1) | DK2029143T3 (enExample) |
| EA (1) | EA016791B1 (enExample) |
| ES (1) | ES2548437T3 (enExample) |
| HU (1) | HUE026457T2 (enExample) |
| IL (1) | IL195916A (enExample) |
| MX (1) | MX2008015954A (enExample) |
| MY (1) | MY152178A (enExample) |
| NZ (1) | NZ597222A (enExample) |
| PL (1) | PL2029143T3 (enExample) |
| PT (1) | PT2029143E (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| EP1658291B1 (en) * | 2003-08-25 | 2013-10-02 | Dogwood Pharmaceuticals, Inc. | Substituted 8-heteroaryl xanthines |
| US7579348B2 (en) * | 2005-02-25 | 2009-08-25 | Pgxhealth, Llc | Derivatives of 8-substituted xanthines |
| WO2006091898A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyrazolyl substituted xanthines |
| WO2006091936A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
| US7884100B2 (en) | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
| US7875608B2 (en) * | 2007-12-17 | 2011-01-25 | Thompson Robert D | Substituted 8-[6-amino-3pyridyl]xanthines |
| WO2022246392A1 (en) | 2021-05-18 | 2022-11-24 | Purnovate, Inc. | Cyclic amide-containing pyridyl xanthines as a 2b antagonists |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| US6060481A (en) | 1998-05-28 | 2000-05-09 | The Penn State Research Foundation | Method for improving insulin sensitivity using an adenosine receptor antagonist |
| GB9817623D0 (en) | 1998-08-13 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| KR20030031466A (ko) * | 2000-02-17 | 2003-04-21 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 포유동물 세포 증식을 조절하기 위한 ａ２ｂ 아데노신수용체 길항 물질의 동정 및 사용 방법 |
| US7304070B2 (en) | 2001-11-09 | 2007-12-04 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| PL370207A1 (en) | 2001-11-09 | 2005-05-16 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists |
| US6977300B2 (en) | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| WO2003063800A2 (en) | 2002-02-01 | 2003-08-07 | King Pharmaceuticals Research And Development, Inc. | 8-heteroaryl xanthine adenosine a2b receptor antagonists |
| US7034070B2 (en) * | 2002-09-27 | 2006-04-25 | Vincent Chuang | Arylalkyl aminofunctional silanes for epoxy laminates |
| US7148229B2 (en) | 2003-02-19 | 2006-12-12 | Hoffman-La Roche Inc. | Sulfonamide substituted xanthine derivatives |
| EP1658291B1 (en) * | 2003-08-25 | 2013-10-02 | Dogwood Pharmaceuticals, Inc. | Substituted 8-heteroaryl xanthines |
| RS52455B (sr) | 2004-09-01 | 2013-02-28 | Gilead Sciences Inc. | Postupak zarastanja rana primenom antagonista adenozinskog a2b receptora |
| US20060053029A1 (en) | 2004-09-03 | 2006-03-09 | Butler Keith R | Methods and systems for providing an enterprise supply management portal |
| US20060159627A1 (en) | 2004-10-15 | 2006-07-20 | Dewan Zeng | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists |
| WO2006091898A2 (en) | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyrazolyl substituted xanthines |
| WO2006091936A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
| US7579348B2 (en) * | 2005-02-25 | 2009-08-25 | Pgxhealth, Llc | Derivatives of 8-substituted xanthines |
| WO2006091896A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyridyl substituted xanthines |
| JP5044823B2 (ja) | 2005-06-16 | 2012-10-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ａ２ｂアデノシンレセプターアンタゴニストのプロドラッグ |
| MX2008011828A (es) * | 2006-03-17 | 2008-09-29 | Cv Therapeutics Inc | Metodo para la prevencion y el tratamiento de enfermedad hepatica utilizando antagonistas del receptor de adenosina a2b. |
| CA2652858A1 (en) * | 2006-06-15 | 2007-12-27 | Targeted Genetics Corporation | Methods for treating target joints in inflammatory arthritis using aav vectors encoding a tnf antagonist |
| US7884100B2 (en) | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
| US7767685B2 (en) | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
| US7875608B2 (en) * | 2007-12-17 | 2011-01-25 | Thompson Robert D | Substituted 8-[6-amino-3pyridyl]xanthines |
| JP5460690B2 (ja) | 2008-03-26 | 2014-04-02 | アドヴィナス・セラピューティックス・リミテッド | アデノシンレセプターアンタゴニストとしてのヘテロ環化合物 |
-
2007
- 2007-06-12 US US11/811,823 patent/US7884100B2/en not_active Expired - Fee Related
- 2007-06-13 BR BRPI0712001A patent/BRPI0712001B8/pt active IP Right Grant
- 2007-06-13 EA EA200900010A patent/EA016791B1/ru unknown
- 2007-06-13 PL PL07796049T patent/PL2029143T3/pl unknown
- 2007-06-13 NZ NZ597222A patent/NZ597222A/xx unknown
- 2007-06-13 HU HUE07796049A patent/HUE026457T2/en unknown
- 2007-06-13 EP EP07796049.0A patent/EP2029143B1/en active Active
- 2007-06-13 CN CN2013100513402A patent/CN103145712A/zh active Pending
- 2007-06-13 JP JP2009515468A patent/JP5417558B2/ja not_active Expired - Fee Related
- 2007-06-13 PT PT77960490T patent/PT2029143E/pt unknown
- 2007-06-13 MX MX2008015954A patent/MX2008015954A/es active IP Right Grant
- 2007-06-13 MY MYPI20084937 patent/MY152178A/en unknown
- 2007-06-13 DK DK07796049.0T patent/DK2029143T3/en active
- 2007-06-13 CA CA2655598A patent/CA2655598C/en active Active
- 2007-06-13 AU AU2007261568A patent/AU2007261568B2/en active Active
- 2007-06-13 KR KR1020097000879A patent/KR101413404B1/ko active Active
- 2007-06-13 ES ES07796049.0T patent/ES2548437T3/es active Active
-
2008
- 2008-12-14 IL IL195916A patent/IL195916A/en active IP Right Grant
-
2010
- 2010-12-14 US US12/967,876 patent/US8258142B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103145712A (zh) | 2013-06-12 |
| US8258142B2 (en) | 2012-09-04 |
| BRPI0712001A2 (pt) | 2012-01-10 |
| BRPI0712001B1 (pt) | 2020-04-07 |
| KR20090029268A (ko) | 2009-03-20 |
| MX2008015954A (es) | 2009-03-06 |
| PL2029143T3 (pl) | 2015-12-31 |
| AU2007261568B2 (en) | 2013-05-16 |
| US20110082139A1 (en) | 2011-04-07 |
| MY152178A (en) | 2014-08-15 |
| PT2029143E (pt) | 2015-10-20 |
| CA2655598A1 (en) | 2007-12-27 |
| EA016791B1 (ru) | 2012-07-30 |
| EP2029143A4 (en) | 2009-07-15 |
| ES2548437T3 (es) | 2015-10-16 |
| JP2010500284A (ja) | 2010-01-07 |
| EA200900010A1 (ru) | 2009-10-30 |
| EP2029143B1 (en) | 2015-07-08 |
| CA2655598C (en) | 2014-10-28 |
| US20080004292A1 (en) | 2008-01-03 |
| AU2007261568A1 (en) | 2007-12-27 |
| IL195916A (en) | 2015-06-30 |
| JP5417558B2 (ja) | 2014-02-19 |
| KR101413404B1 (ko) | 2014-06-27 |
| IL195916A0 (en) | 2009-09-01 |
| HUE026457T2 (en) | 2016-05-30 |
| DK2029143T3 (en) | 2015-09-21 |
| US7884100B2 (en) | 2011-02-08 |
| NZ597222A (en) | 2013-06-28 |
| EP2029143A2 (en) | 2009-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0413922B8 (pt) | xantinas de 8-heteroarila substituída | |
| BRPI0712001B8 (pt) | composto 8-[6-amino-3-piridil] xantinas substituídas e composição farmacêutica contendo o dito composto | |
| BRPI0813218A2 (pt) | Composto, composição farmacêutica que o contém como princípio ativo e uso do composto. | |
| DK2018388T3 (da) | Bisadenosinforbindelser som adenosin A2A-receptoragonister | |
| CR20140515A (es) | Prolinamida-2-5-oxo fenilmetil-n-sustituidos como receptores antagonistas y sus metodos de uso | |
| BRPI0910182B8 (pt) | composto de fórmula (i), composição farmacêutica e uso de um composto | |
| DK2013211T3 (da) | Purinderivater til anvendelse som adenosin-A2A-receptoragonister | |
| CO6531451A2 (es) | Compuesto de pirrolo[2,3-d]pirimidina | |
| ECSP10010095A (es) | 2'-fluoro-2'-desoxitetrahidrouridinas como inhibidores de citidina desaminasa | |
| BRPI0716936A2 (pt) | derivados de adenosina como antigonistas de receptor de a2a | |
| CO6390082A2 (es) | Compuestos organicos | |
| CO6321189A2 (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
| WO2009043320A3 (en) | Substituted 6-(alkylbenzylamino)purine derivatives for use as cytokinin receptor antagonists and preparations containing these derivatives | |
| HN2008001530A (es) | Compuestos de amino pirimidina 2,6- sustituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2 | |
| ECSP11010812A (es) | Complejo de mineral-aminoácido polisacárido | |
| GT200500272A (es) | 2-anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y su uso como medicamentos | |
| CL2008001048A1 (es) | Compuestos derivados de heterociclos nitrogenados; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como antibacterianos. | |
| EA201100303A1 (ru) | Производные пиразоло[5,1-b]оксазола в качестве антагонистов cfr1 | |
| WO2006091898A3 (en) | Pyrazolyl substituted xanthines | |
| CL2007003483A1 (es) | Compuestos derivados de indol-2-il-carbonil-espiro-piperidina, antagonistas del receptor de la v1a; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de hipertension, dismeno | |
| WO2008116185A3 (en) | Substituted pyrimidines as adenosine receptor antagonists | |
| UA105164C2 (en) | Substituted 8-[6-amino-3-pyridyl]xanthines | |
| CL2007003556A1 (es) | Compuestos derivados de 6-(piperidin-4-ilamino)piridazin-3-carbonitrilos, antagonistas del receptor de dopamina 2 de rapida disociacion; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el | |
| NI201100015A (es) | Compuestos novedosos activos como antagonistas de receptor muscarínico. | |
| BRPI0707560B8 (pt) | combinação de análogos de somatostatina com seletividade diferente para subtipos de receptores de somatostatina humana, seu uso, composição farmacêutica, e embalagem comercial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 3A ANUIDADE. |
|
| B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: REFERENTE A DESPACHO 8.6 NA RPI 2161 DE 05/06/2012. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 6A. ANUIDADE(S). |
|
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: TROVIS PHARMACEUTICALS LLC (US) |
|
| B25A | Requested transfer of rights approved |
Owner name: TROVIS PHARMACEUTICALS HOLDINGS, INC. (US) |
|
| B25A | Requested transfer of rights approved |
Owner name: CLINICAL DATA, INC. (US) |
|
| B25A | Requested transfer of rights approved |
Owner name: DOGWOOD PHARMACEUTICALS, INC. (US) |
|
| B25A | Requested transfer of rights approved |
Owner name: FOREST LABORATORIES HOLDINGS LIMITED (BM) |
|
| B25A | Requested transfer of rights approved |
Owner name: DOGWOOD PHARMACEUTICALS, INC. (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/04/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/06/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B25A | Requested transfer of rights approved |
Owner name: ALLERGAN SALES, LLC (US) |